Comprehensive Psychiatry
Volume 48, Issue 6 , Pages 497-503 , November 2007

Medication use patterns and two-year outcome in first-admission patients with major depressive disorder with psychotic features

  • Thomas J. Craig

      Affiliations

    • Department of Veterans Affairs, Office of Quality and Performance, Washington, DC 20024, USA
    • Corresponding Author InformationCorresponding author. Springfield, VA 22152, USA.
    • ,
  • Steven Grossman

      Affiliations

    • Department of Psychiatry and Behavioral Science, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
    • ,
  • Evelyn J. Bromet

      Affiliations

    • Department of Psychiatry and Behavioral Science, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
    • ,
  • Laura J. Fochtmann

      Affiliations

    • Department of Psychiatry and Behavioral Science, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
    • ,
  • Gabrielle A. Carlson

      Affiliations

    • Department of Psychiatry and Behavioral Science, State University of New York at Stony Brook, Stony Brook, NY 11794, USA

References 

  1. Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry. 1999;60:116–118
  2. Dannon PN, Lowengrub K, Gonopolski Y, Kotler M. Current and emerging somatic treatment strategies in psychotic major depression. Expert Rev Neurotherapeutics. 2006;6:73–80
  3. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?. Am J Psychiatry. 1992;150:733–745
  4. Coryell W, Lavori P, Endicott J, Keller M, VanEerdewegh M. Outcome in schizoaffective, psychotic and nonpsychotic depression: course during a six-to 24-month follow-up. Arch Gen Psychiatry. 1984;41:787–791
  5. Kendler KS. Mood-incongruent psychotic affective illness. a historical and empirical review. Arch Gen Psychiatry. 1991;48:362–369
  6. Maj M, Pirozzi R, Caprio EL. Major depression with mood incongruent psychotic features: a distinct entity or a more severe subtype of depression?. Acta Psychiatr Scand. 1990;82:439–444
  7. Charney DS, Nelson JC. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry. 1981;138:328–333
  8. Lykouras E, Malliaras D, Christodoulou GN, Papakostas Y, Voulgari A, Tzonou A, et al. Delusional depression: phenomenology and response to treatment. A prospective study. Acta Psychiatr Scand. 1986;73:324–329
  9. Tohen M, Hennen J, Zarate CM, Baldessarini RJ, Strakowski SM, Stoll AL, et al. Two-year syndromal and functional recovery in 219 cases of first episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157:220–228
  10. Wykstra J, Lijmer J, Balk F, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev. 2005;(4):CD004044
  11. Bromet E, Schwartz J, Fennig S, Geller L, Jandorf L, Kovasznay B, et al. The epidemiology of psychosis: the Suffolk County mental health project. Schizophr Bull. 1992;18:243–255
  12. Spitzer RL, Williams J, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry. 1992;49:624–629
  13. Fennig S, Kovasznay B, Rich C, Ram R, Pato C, Miller A, et al. Six-month stability of psychiatric diagnoses in first admission patients with psychosis. Am J Psychiatry. 1994;151:1200–1208
  14. Gibson PJ, Lavelle J, Bromet E. Building a useful pharmacotherapy data set from multiple sources. In: Poster presented at the Annual Conference of the Association of Health Services Researchers, Chicago, Ill. 1999;
  15. Patterson DA, Lee MS. Field trial of the Global Assessment of Functioning Scale–Modified. Am J Psychiatry. 1995;152:1386–1388
  16. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al. Schizophrenia: manifestations, incidence and course in different cultures: a World Health Organization ten-country study. Psychol Med Monogr Suppl. 1992;20:1–97
  17. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156:1000–1006
  18. Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RMA. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry. 1986;143:24–28
  19. Keller MB, Harrison W, Fawcett JA, Gelenberg A, Hirschfeld RM, Klein D, et al. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacol Bull. 1995;31:205–212
  20. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. STAR*D study team: evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40
  21. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. STAR*D study team: bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231–1242
  22. Fava M, Rush AJ, Wisniewski SR, Alpert JE, McGrath PJ, Thase ME, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161–1172
  23. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;1531–1541
  24. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. STAR*D team: medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–1252
  25. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163:1519–1530
  26. Maj M, Arena F, Lovero N, Pirozzi R, Kemali D. Factors associated with response to lithium prophylaxis in DSMIII major depression and bipolar disorder. Pharmacopsychiatry. 1985;18:309–313
  27. Valenstein M, McCarthy JF, Austin KL, Greden JF, Young EA, Blow FC. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry. 2006;163:1219–1225
  28. Flint AJ, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry. 1998;13:23–28
  29. Petrides G, Fink M, Husain MM, Knapp RG, Rush AJ, Mueller M, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. JECT. 2001;17:244–253
  30. Cochran SD. Compliance with lithium regimens in the outpatient treatment of bipolar affective disorders. J Compliance Health Care. 1986;1:153–170
  31. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, et al. Olanzapine-fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004;24:365–373
  32. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, et al. The pharmacological treatment of delusional depression. Am J Psychiatry. 1985;142:430–436

PII: S0010-440X(07)00084-3

doi: 10.1016/j.comppsych.2007.06.005

Comprehensive Psychiatry
Volume 48, Issue 6 , Pages 497-503 , November 2007

Article Tools